Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779519 · ClinicalTrials.gov registry record · Phase 2
Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss
A Phase 2 study, sponsored by vTv Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00779519 is a Phase 2 study that has completed, run by vTv Therapeutics. The registered enrollment target is 100 participants.
The verdict
NCT00779519, a Phase 2 study, has completed, sponsored by vTv Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight. One of the most studied pathways involves the melanocortin receptor. Agouti-related protein (AgRP) and alpha-melanocyte stimulating hormone (alphaMSH)have been shown to play an integral role in food intake and body weight. It is reasonable to speculate that if there is an imbalance of alphaMSH and AgRP exist in obese individuals and inhibiting the activity of AgRP may be of therapeutic benefit in treating obesity.
Interventions
- DRUG Placebo
- DRUG TTP435
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779519
The ClinicalTrials.gov registry entry for NCT00779519 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is vTv Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00779519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00779519 about?
NCT00779519 is a clinical study titled "Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss". Multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight. One of the most studied pathways involves the melanocortin receptor. Agouti-related protein (AgRP) and alpha-melanocyte stimulating hormone (alphaMSH)have ...
What is the current status of trial NCT00779519?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2009-02.
What interventions are being tested in trial NCT00779519?
The interventions under investigation include: Placebo (DRUG), TTP435 (DRUG).
Who is sponsoring clinical trial NCT00779519?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.